CompaniesThe Medicines Company

The Medicines Company

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (67)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

76,583

By Phase

PHASE3: 29PHASE4: 9PHASE1: 6PHASE2: 13PHASE1/PHASE2: 1NA: 5

By Status

COMPLETED: 50TERMINATED: 9WITHDRAWN: 7UNKNOWN: 1

Clinical Trials Pipeline67 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Today

NCT00043940

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 1999

Completion: Not specified

NCT00043940

NCT00043277

Study Of Angiomax In Infants Under Six Months With Thrombosis

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2002

Completion: Dec 31, 2004

NCT00073593

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2003

Completion: Not specified

NCT00073593

NCT00093158

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2003

Completion: Jan 31, 2007

NCT00073580

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 31, 2003

Completion: Not specified

NCT00073580

NCT00093262

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2003

Completion: Oct 31, 2004

NCT00093249

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2004

Completion: Nov 30, 2004

NCT00079508

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Not specified

NCT00079508

NCT00079586

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Nov 30, 2004

NCT00093184

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Dec 31, 2005

NCT00093886

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Apr 30, 2005

NCT00093925

Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2004

Completion: Sep 30, 2006

NCT00093912

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2004

Completion: Nov 30, 2006

NCT00419055

Outpatient Percutaneous Coronary Intervention

Phase: N/A

Role: Collaborator

Start: Aug 31, 2004

Completion: Aug 31, 2006

NCT00102674

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2005

Completion: May 31, 2005

NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Phase: Phase 3

Role: Collaborator

Start: Mar 31, 2005

Completion: Nov 30, 2010

NCT00433966

NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2006

Completion: Jun 30, 2010

NCT00369837

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2006

Completion: Feb 28, 2007

NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2006

Completion: Jun 30, 2010

NCT00476944

Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI

Phase: Phase 4

Role: Collaborator

Start: Sep 30, 2006

Completion: Not specified

NCT00476944

NCT00503126

Bivalirudin as a Procedural Anticoagulant in Pediatrics

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2007

Completion: Jul 31, 2008

NCT00666328

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2008

Completion: Apr 30, 2010

NCT00699504

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2008

Completion: Nov 30, 2008

NCT00759083

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Phase: Phase 4

Role: Lead Sponsor

Start: Sep 30, 2008

Completion: May 10, 2010

NCT00767507

Maintenance of Platelet Inhibition With Cangrelor

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 31, 2008

Completion: Jul 31, 2011

NCT00799604

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2008

Completion: Oct 31, 2009

NCT00803634

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2008

Completion: Mar 31, 2012

NCT00842374

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

Phase: N/A

Role: Collaborator

Start: Dec 31, 2008

Completion: Dec 31, 2012

NCT01011504

Utilisation of Angiox® in European Practice

Phase: N/A

Role: Lead Sponsor

Start: May 31, 2009

Completion: Dec 31, 2010

NCT00978822

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Phase: Phase 2

Role: Collaborator

Start: Jun 30, 2009

Completion: Dec 31, 2012

NCT00952081

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

Phase: Phase 4

Role: Collaborator

Start: Jul 31, 2009

Completion: Feb 28, 2010

NCT01033370

A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)

Phase: Phase 4

Role: Collaborator

Start: Nov 30, 2009

Completion: Aug 31, 2012

NCT01087723

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2010

Completion: Aug 31, 2014

NCT01087723

NCT01042574

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

Phase: Phase 4

Role: Collaborator

Start: May 31, 2010

Completion: Dec 31, 2010

NCT01156571

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2010

Completion: Dec 31, 2012

NCT01535222

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2010

Completion: Jun 30, 2011

NCT01167634

University Of Pennsylvania Weight Loss Study

Phase: N/A

Role: Collaborator

Start: May 24, 2011

Completion: Jul 31, 2016

NCT01167634

NCT01406236

SAFE-PCI for Women

Phase: N/A

Role: Collaborator

Start: Aug 31, 2011

Completion: Sep 30, 2013

NCT01526876

The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients

Phase: Phase 4

Role: Collaborator

Start: Nov 30, 2011

Completion: Dec 19, 2012

NCT01480531

Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection

Phase: N/A

Role: Collaborator

Start: Dec 31, 2011

Completion: Dec 31, 2012

NCT01530399

Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2012

Completion: Nov 30, 2012

NCT01860105

Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2012

Completion: Jan 31, 2013

NCT01651780

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 31, 2012

Completion: Jun 30, 2015

NCT01766466

Cangrelor Ticagrelor Transition Study

Phase: Phase 2

Role: Lead Sponsor

Start: Jan 31, 2013

Completion: Feb 28, 2013

NCT01852019

Cangrelor Prasugrel Transition Study

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2013

Completion: Jul 31, 2013

NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Phase: Phase 3

Role: Collaborator

Start: Jul 1, 2013

Completion: Apr 26, 2018

NCT01813435

NCT01913483

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 24, 2013

Completion: Mar 16, 2016

NCT01979445

Cangrelor to Clopidogrel or Prasugrel Transition Study

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 2, 2013

Completion: Jan 20, 2014

NCT02081443

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

Phase: N/A

Role: Collaborator

Start: Apr 30, 2014

Completion: Oct 31, 2015

NCT02171065

PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.

Phase: N/A

Role: Collaborator

Start: Jun 30, 2014

Completion: May 31, 2020

NCT02171065

NCT04592380

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2014

Completion: Nov 30, 2016

NCT02565147

Bivalirudin Infusion for Ventricular Infarction Limitation

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 19, 2014

Completion: Jun 14, 2016

NCT02314442

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase: Phase 1

Role: Collaborator

Start: Dec 31, 2014

Completion: Nov 30, 2015

NCT02395653

Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 29, 2015

Completion: Sep 12, 2016

NCT02389907

Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care

Phase: N/A

Role: Lead Sponsor

Start: Jun 30, 2015

Completion: Aug 31, 2015

NCT02471690

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2015

Completion: Apr 30, 2016

NCT02452918

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase: Phase 4

Role: Lead Sponsor

Start: Sep 29, 2015

Completion: Jul 5, 2016

NCT02678923

MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial

Phase: Phase 1/2

Role: Lead Sponsor

Start: Dec 3, 2015

Completion: Oct 26, 2016

NCT02597127

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Phase: Phase 2

Role: Lead Sponsor

Start: Jan 31, 2016

Completion: Jun 7, 2017

NCT02800590

Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2016

Completion: Jun 30, 2017

NCT02963311

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 13, 2016

Completion: Oct 8, 2018

NCT02925416

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Phase: Phase 4

Role: Lead Sponsor

Start: Jan 24, 2017

Completion: Jun 20, 2017

NCT03159416

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 22, 2017

Completion: Mar 24, 2018

NCT03400800

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 1, 2017

Completion: Aug 27, 2019

NCT03021083

IONSYS Feasibility Study

Phase: Phase 4

Role: Collaborator

Start: Nov 1, 2017

Completion: Nov 1, 2017

NCT03397121

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 28, 2017

Completion: Sep 17, 2019

NCT03399370

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 21, 2017

Completion: Sep 17, 2019

Hover over trial bars to see details